Challenges in the evaluation, consent, ethics and history of early clinical trials - Implications of the Tuskegee 'trial' for safer and more ethical clinical trials

Current Opinion in Molecular Therapeutics

Volumn 11, Issue 5, 2009, Pages 481-484

  Lowenstein, P R ^a,b   Lowenstein, E D ^a   Castro, M G ^a,b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEW DRUG; PENICILLIN G;

CLINICAL RESEARCH; CLINICAL TRIAL; EDITORIAL; EVALUATION; HISTORY OF MEDICINE; HUMAN; INFORMED CONSENT; PATIENT SAFETY; RESEARCH ETHICS; SYPHILIS; UNITED STATES;

CLINICAL TRIALS AS TOPIC; HUMANS; INFORMED CONSENT;

EID: 70349912164     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (25)

1. Emanuel EJ, Crouch RA, Arras JD, Moreno JD, Grady C (Eds): Ethical and Regulatory Aspects of Clinical Research. The Johns Hopkins University Press, Baltimore, MD, USA (2003).
2. Lowenstein PR: Clinical trials in gene therapy: Ethics of informed consent and the future of experimental medicine. Curr Opin Mol Ther (2008) 10(5):428-430.
3. Lowenstein PR: A call for physiopathological ethics. Mol Ther (2008) 16(11):1771-1772.
4. Kimmelman J: The ethics of human gene transfer. Nat Rev Genet (2008) 9(3):239-244.
5. Berry DA: Bayesian clinical trials. Nat Rev Drug Discov (2006) 5(1):27-36.
6. Kadane JB: Progress toward a more ethical method for clinical trials. J Med Philos (1986) 11(4):385-404.
7. Kadane JB (Ed): Bayesian Methods and Ethics in a Clinical Trial Design. John Wiley & Sons, Chichester, UK (1996).
8. Ziliak ST, McCloskey DN (Eds): The Cult of Statistical Significance. The University of Michigan Press, Ann Arbor, MI, USA (2009).
9. Lederer SE (Ed): Subjected to Science: Human Experimentation in America Before the Second World War. The Johns Hopkins University Press, Baltimore, MD, USA (1995).
10. Jones JH (Ed): Bad Blood: The Tuskegee Syphilis Experiment. Free Press, New York, NY, USA (1993).
11. Final Report of the Tuskegee Syphilis Study Ad Hoc Advisory Panel. US Department of Health, Education, and Welfare. Public Health Service, Washington DC: Government Printing Office (1972) HE 20.2:T 87.
12. Piantadosi S: Rigor in monitoring clinical trials is ethical. J Clin Oncol (2008) 26(4):683-685.
13. Fetting JH, Siminoff LA, Piantadosi S, Abeloff MD, Damron DJ, Sarsfield AM: Effect of patients' expectations of benefit with standard breast cancer adjuvant chemotherapy on participation in a randomized clinical trial: A clinical vignette study. J Clin Oncol (1990) 8(9):1476-1482. (Pubitemid 20301178)
14. Piantadosi S: Hazards of small clinical trials. J Clin Oncol (1990) 8(1):1-3.
15. Kim SY: Assessing and communicating the risks and benefits of gene transfer clinical trials. Curr Opin Mol Ther (2006) 8(5):384-389. (Pubitemid 44566779)
16. Frank SA, Wilson R, Holloway RG, Zimmerman C, Peterson DR, Kieburtz K, Kim SY: Ethics of sham surgery: Perspective of patients. Mov Disord (2008) 23(1):63-68. (Pubitemid 351281219)
17. Kim SY, Frank S, Holloway R, Zimmerman C, Wilson R, Kieburtz K: Science and ethics of sham surgery: A survey of Parkinson disease clinical researchers. Arch Neurol (2005) 62(9):1357-1360. (Pubitemid 41352051)
18. Schuman SH, Olansky S, Rivers E, Smith CA, Rambo DS: Untreated syphilis in the male negro; background and current status of patients in the Tuskegee study. J Chronic Dis (1955) 2(5):543-558.
19. Rivers E, Schuman SH, Simpson L, Olansky S: Twenty years of followup experience in a long-range medical study. Public Health Rep (1953) 68(4):391-395.
20. Houede N, Thall PF, Nguyen H, Paoletti X, Kramar A: Utility-based optimization of combination therapy using ordinal toxicity and efficacy in phase I/II trials. Biometrics (2009):doi: 10.1111/j.1541-0420.2009.01302.
21. Thall PF: A review of phase 2-3 clinical trial designs. Lifetime Data Anal (2008) 14(1):37-53.
22. Thall PF, Wathen JK: Practical Bayesian adaptive randomisation in clinical trials. Eur J Cancer (2007) 43(5):859-866. (Pubitemid 46366693)
23. Wathen JK, Thall PF: Bayesian adaptive model selection for optimizing group sequential clinical trials. Stat Med (2008) 27(27):5586-5604.
24. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D et al; National Cancer Institute of Canada Clinical Trials Group: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (2007) 25(15):1960-1966. (Pubitemid 46972777)
25. Miksad RA, Schnipper L, Goldstein M: Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value? J Clin Oncol (2007) 25(28):4506-4507. (Pubitemid 350013866)